PURPOSE: The Study of Tamoxifen and Raloxifene (STAR) demonstrated that raloxifene was as effective as tamoxifen in reducing the risk of invasive breast cancer (IBC) in postmenopausal women and had lower risks of thromboembolic events, endometrial cancer, and cataracts but had a nonstatistically significant higher risk of noninvasive breast cancer. There is a need to summarize the risks and benefits of these agents. PATIENTS AND METHODS: Baseline incidence rates of IBC and other health outcomes, absent raloxifene and tamoxifen, were estimated from breast cancer chemoprevention trials; the Surveillance, Epidemiology and End Results Program; and the Women's Health Initiative. Effects of raloxifene and tamoxifen were estimated from STAR and the Breast Cancer Prevention Trial. We assigned weights to health outcomes to calculate the net benefit from raloxifene compared with placebo and tamoxifen compared with placebo. RESULTS: Risks and benefits of treatment with raloxifene or tamoxifen depend on age, race, breast cancer risk, and history of hysterectomy. Over a 5-year period, postmenopausal women with an intact uterus had a better benefit/risk index for raloxifene than for tamoxifen. For postmenopausal women without a uterus, the benefit/risk ratio was similar. The benefits and risks of raloxifene and tamoxifen are described in tables that can help identify groups of women for whom the benefits outweigh the risks. CONCLUSION: We developed a benefit/risk index to quantify benefits from chemoprevention with tamoxifen or raloxifene. This index can complement clinical evaluation in deciding whether to initiate chemoprevention and in comparing the benefits and risks of raloxifene versus tamoxifen.
PURPOSE: The Study of Tamoxifen and Raloxifene (STAR) demonstrated that raloxifene was as effective as tamoxifen in reducing the risk of invasive breast cancer (IBC) in postmenopausal women and had lower risks of thromboembolic events, endometrial cancer, and cataracts but had a nonstatistically significant higher risk of noninvasive breast cancer. There is a need to summarize the risks and benefits of these agents. PATIENTS AND METHODS: Baseline incidence rates of IBC and other health outcomes, absent raloxifene and tamoxifen, were estimated from breast cancer chemoprevention trials; the Surveillance, Epidemiology and End Results Program; and the Women's Health Initiative. Effects of raloxifene and tamoxifen were estimated from STAR and the Breast Cancer Prevention Trial. We assigned weights to health outcomes to calculate the net benefit from raloxifene compared with placebo and tamoxifen compared with placebo. RESULTS: Risks and benefits of treatment with raloxifene or tamoxifen depend on age, race, breast cancer risk, and history of hysterectomy. Over a 5-year period, postmenopausal women with an intact uterus had a better benefit/risk index for raloxifene than for tamoxifen. For postmenopausal women without a uterus, the benefit/risk ratio was similar. The benefits and risks of raloxifene and tamoxifen are described in tables that can help identify groups of women for whom the benefits outweigh the risks. CONCLUSION: We developed a benefit/risk index to quantify benefits from chemoprevention with tamoxifen or raloxifene. This index can complement clinical evaluation in deciding whether to initiate chemoprevention and in comparing the benefits and risks of raloxifene versus tamoxifen.
Authors: M H Gail; J P Costantino; J Bryant; R Croyle; L Freedman; K Helzlsouer; V Vogel Journal: J Natl Cancer Inst Date: 1999-11-03 Impact factor: 13.506
Authors: J P Costantino; M H Gail; D Pee; S Anderson; C K Redmond; J Benichou; H S Wieand Journal: J Natl Cancer Inst Date: 1999-09-15 Impact factor: 13.506
Authors: M H Gail; L A Brinton; D P Byar; D K Corle; S B Green; C Schairer; J J Mulvihill Journal: J Natl Cancer Inst Date: 1989-12-20 Impact factor: 13.506
Authors: Garnet L Anderson; Marian Limacher; Annlouise R Assaf; Tamsen Bassford; Shirley A A Beresford; Henry Black; Denise Bonds; Robert Brunner; Robert Brzyski; Bette Caan; Rowan Chlebowski; David Curb; Margery Gass; Jennifer Hays; Gerardo Heiss; Susan Hendrix; Barbara V Howard; Judith Hsia; Allan Hubbell; Rebecca Jackson; Karen C Johnson; Howard Judd; Jane Morley Kotchen; Lewis Kuller; Andrea Z LaCroix; Dorothy Lane; Robert D Langer; Norman Lasser; Cora E Lewis; JoAnn Manson; Karen Margolis; Judith Ockene; Mary Jo O'Sullivan; Lawrence Phillips; Ross L Prentice; Cheryl Ritenbaugh; John Robbins; Jacques E Rossouw; Gloria Sarto; Marcia L Stefanick; Linda Van Horn; Jean Wactawski-Wende; Robert Wallace; Sylvia Wassertheil-Smoller Journal: JAMA Date: 2004-04-14 Impact factor: 56.272
Authors: J Cuzick; J Forbes; R Edwards; M Baum; S Cawthorn; A Coates; A Hamed; A Howell; T Powles Journal: Lancet Date: 2002-09-14 Impact factor: 79.321
Authors: Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene Journal: JAMA Date: 2002-07-17 Impact factor: 56.272
Authors: B Fisher; J P Costantino; D L Wickerham; C K Redmond; M Kavanah; W M Cronin; V Vogel; A Robidoux; N Dimitrov; J Atkins; M Daly; S Wieand; E Tan-Chiu; L Ford; N Wolmark Journal: J Natl Cancer Inst Date: 1998-09-16 Impact factor: 13.506
Authors: U Veronesi; P Maisonneuve; A Costa; V Sacchini; C Maltoni; C Robertson; N Rotmensz; P Boyle Journal: Lancet Date: 1998-07-11 Impact factor: 79.321
Authors: Garnet L Anderson; Rowan T Chlebowski; Aaron K Aragaki; Lewis H Kuller; JoAnn E Manson; Margery Gass; Elizabeth Bluhm; Stephanie Connelly; F Allan Hubbell; Dorothy Lane; Lisa Martin; Judith Ockene; Thomas Rohan; Robert Schenken; Jean Wactawski-Wende Journal: Lancet Oncol Date: 2012-03-07 Impact factor: 41.316
Authors: Laura L Reimers; Parijatham S Sivasubramanian; Dawn Hershman; Mary Beth Terry; Heather Greenlee; Julie Campbell; Kevin Kalinsky; Matthew Maurer; Ramona Jayasena; Rossy Sandoval; Maria Alvarez; Katherine D Crew Journal: Breast J Date: 2015-04-16 Impact factor: 2.431
Authors: R Rizzoli; J J Body; A DeCensi; A De Censi; J Y Reginster; P Piscitelli; M L Brandi Journal: Osteoporos Int Date: 2012-01-20 Impact factor: 4.507
Authors: Chelsea Anderson; Anne Marie Meyer; Stephanie B Wheeler; Lei Zhou; Katherine E Reeder-Hayes; Hazel B Nichols Journal: Oncologist Date: 2017-04-13
Authors: Emily E Anderson; Silvia Tejeda; Kimberly Childers; Melinda R Stolley; Richard B Warnecke; Kent F Hoskins Journal: J Oncol Pract Date: 2015-06-02 Impact factor: 3.840
Authors: Stephanie R Land; Farzana L Walcott; Qing Liu; D Lawrence Wickerham; Joseph P Costantino; Patricia A Ganz Journal: J Natl Cancer Inst Date: 2015-11-27 Impact factor: 13.506